Despite its best efforts, medical device maker C.R. Bard (NYSE:BCR) wasn’t able to reverse a $2 million bellwether jury verdict finding the company’s troubled Avaulta transvaginal mesh was defective and responsible for harming a patient.
Gynecological
FDA responds to patient uprising over Bayer’s Essure birth control implant
Bard seeks to recoup legal costs in dismissed Avaulta bellwether
First bellwether date set for Boston Scientific in pelvic mesh lawsuits
The 1st bellwether trial in the multi-district litigation filed over Boston Scientific‘s (NYSE:BSX) pelvic mesh products is slated for early next year, a federal judge ordered this week.
Laborie Medical buys UroMed’s pelvic rehab biz
Laborie Medical Technologies said it acquired the pelvic muscle rehabilitation business of UroMed Technology for an undisclosed amount.
Toronto-based Laborie, which is owned by private equity company Audax Group, said the UroMed business expands its offering in the pelvic muscle rehab and conservative therapy space.
Pelvic mesh makers look to settle lawsuits
Five medical device companies that make pelvic mesh implants are hoping to negotiate settlements for the more than 30,000 pending lawsuits they’re facing in the U.S., anonymous sources told Bloomberg.
Pelvic mesh: Bard reportedly settles another Avaulta case
Another study finds robotic surgery equal but pricier
Hysterectomies using surgical robots like Intuitive Surgical‘s (NSDQ:ISRG)’s da Vinci device are no better than hysterectomies performed laparoscopically, but cost a lot more per procedure, according to a study in the journal Obstetrics & Gynecology.
Bard settles 2nd Avaulta bellwether
French pelvic mesh maker dodges Coloplast personal injury lawsuit
The French manufacturer of the mesh used in Coloplast’s embattled Aris transobturator tape system was dismissed from one of the thousands of personal injury lawsuits filed over pelvic mesh systems.
Roche dishes out $220M for Constitution Medical Investors
Biotech titan Roche acquired Boston, Mass.-based medical device company Constitutional Medical Investors for a reported $220 million plus possible milestones.